BYSI

BeyondSpring, Inc.

2.46 USD
-0.07 (-2.77%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BeyondSpring, Inc. stock is down -28.28% since 30 days ago. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 June’s closed higher than May.

About BeyondSpring, Inc.

Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.